Business Wire

Lineage Opens New Fully Automated Cool Port II High-Rise Cold Storage Facility in the Port of Rotterdam

23.11.2022 17:30:00 EET | Business Wire | Press release

Share

Lineage Logistics, LLC (“Lineage” or the “Company”), one of the world’s leading temperature-controlled industrial REIT and logistics solutions providers, today officially opened its fully-automated Cool Port II cold storage facility in the Port of Rotterdam, Netherlands, adding a key European port location to Lineage’s global network of best-in-class cold storage facilities.

The fully automated deep-freeze high bay warehouse offers 60,000 pallet locations, three automated truck unloading systems and a full range of services to safely store food products and bring them to market. Strategically located in Europe’s largest sea port, the new Cool Port II facility co-located next to Cool Port I gives customers the option of tri-modal connections by sea, rail and road, connecting Lineage’s growing network from Europe to the UK and far beyond.

The facility features the industry’s most advanced automation solutions, helping to address labour volatility, provide fast and efficient service to clients and reduce the site’s energy consumption, all while ensuring the highest level of food safety and reduction of food waste. Cool Port II utilises data-driven solutions to optimise its energy use, with precision cooling cycles to minimise energy leakage and a high-rise design that maximises storage density and reduces the site’s energy footprint. Best-in-class refrigeration technology and the latest systems for temperature control combined with the energy-saving design of the facility make Cool Port II a frontrunner in energy efficiency in the cold storage sector. The site is up to 45% more energy efficient than a conventional cold storage facility.

“Our new Cool Port II facility highlights the best-in-class approach that makes Lineage a unique and forward-looking partner for our customers,” said Harld Peters, President of Europe at Lineage. “In addition to its strategic location, Cool Port II utilises the latest in automation technology. Our aim is to be a driving force behind greening the supply chain, investing in our people and our facilities to deploy the very latest in cold storage technology. In this way, we can reduce our energy footprint while providing the solutions our customers need to deliver food safely and efficiently throughout Europe and beyond.”

In addition to the increased energy efficiency of a fully automated facility, the building is constructed to meet the highest BREEAM sustainability standards. Cool Port has over 11,000 solar panels on its roof making Lineage one of the leading companies in the Port of Rotterdam when it comes to generating solar power for in-house use. As a Climate Pledge signatory, Lineage is committed to achieving net-zero carbon emissions across its operations by 2040.

“We are proud to open this state-of-the-art facility, a multi-modal facility that is well connected by road, rail and barges and the only cold store facility in Rotterdam connected with the Short Sea Terminals. We aim to provide Lineage’s customers easy access to a strong and growing network to deliver their product safely and efficiently,” said Mark Ketelaar, Regional Vice President for the Benelux Region at Lineage Logistics. “Cool Port II offers a complete range of services and state-of-the-art facilities to maximise efficiency and safe handling of the products in our care.”

In recent years Lineage has expanded its network across Europe, creating a one-stop-shop solution for customers across the continent. This reduces the complexity of moving food between countries, reduces food waste and makes the distribution of food more efficient and resilient.

About Lineage Logistics

Lineage Logistics is one of the world’s leading temperature-controlled industrial REIT and logistics solutions provider. It has a global network of over 400 strategically located facilities totalling over 2 billion cubic feet of capacity, which spans 20 countries across North America, Europe and Asia-Pacific. Lineage’s industry-leading expertise in end-to-end logistical solutions, its unrivalled real estate network and the development and deployment of innovative technology help increase distribution efficiency, advance sustainability, minimize supply chain waste and, most importantly, as a Visionary Partner of Feeding America, help feed the world. In recognition of the company’s leading innovations and sustainability initiatives, Lineage was No. 17 in the 2021 CNBC Disruptor 50 list, the No 1. Data Science company, and 23rd overall, on Fast Company’s 2019 list of The World’s Most Innovative Companies, in addition to being included on Fortune’s Change The World list in 2020. Lineage is a 2022 U.S. Best Managed Company, a recognition by Deloitte Private and The Wall Street Journal for private companies that demonstrate excellence in strategic planning and execution, corporate culture and financial results. (www.lineagelogistics.com)

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Lineage Logistics
Magnus Franklin
+32471620575
magnus.franklin@teneo.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Provides Progress Update Regarding RelabotulinumtoxinA Regulatory Submission in the United States1.7.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD) today provided progress updates regarding the regulatory review of its pending Biologics License Application (“BLA”) for RelabotulinumtoxinA with the U.S. Food and Drug Administration (“FDA”). The Company has received a Complete Response Letter (CRL) from the FDA with comments related to observations during manufacturing site inspection and analytical method optimization. As part of its review, the FDA conducted a Pre-License Inspection (PLI) of Galderma’s manufacturing site. All other aspects of the BLA, including safety- and efficacy-related parts, did not solicit deficiencies to be addressed. The FDA made observations during the PLI for which Galderma is putting in place corrective and preventive actions. Galderma will also be seeking further guidance through continued open dialogue with the FDA toward resolution of the relevant observations. Galderma plans to rapidly respond to the CRL and advancing RelabotulinumtoxinA in the U.S. remains a top priority. The ob

EVE Energy Showcases All-Scenario Energy Storage Solutions at The Smarter E Europe 20261.7.2026 04:45:00 EEST | Press release

EVE Energy unveiled its Mr. Big Family series, a 6.9+ MWh energy storage system, and all-scenario energy storage solutions at Intersolar Europe in Munich. Drawing on traceable large-cell technology, proven large-scale energy storage project delivery experience, and global delivery capabilities, the company is addressing Europe's diverse energy storage requirements across utility-scale, commercial & industrial (C&I ), and data center segments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260630889717/en/ EVE Energy showcases its Mr. Giant 3.0 6.9+ MWh energy storage system at The Smarter E Europe 2026 in Munich, Germany Advancing Large-Cell Technology with Global Project Validation As one of the first companies to focus on large-capacity energy storage cells, EVE Energy has iteratively upgraded its cell platform from 560 Ah and 628 Ah to 702 Ah, adhering to a stacking process route throughout. At the exhibition, the Mr. Gia

Bending Spoons S.p.A. announces pricing of initial public offering1.7.2026 02:56:00 EEST | Press release

Bending Spoons S.p.A. (“Bending Spoons”), a leading technology company, today announces the pricing of its initial public offering (“IPO”) at $29.00 per share. A total of 57,971,015 ordinary shares are being offered, of which 34,398,640 shares are being offered by Bending Spoons and 23,572,375 shares are being offered by certain selling shareholders (the “Selling Shareholders”). Bending Spoons will not receive any proceeds from any sale of shares by the Selling Shareholders. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “BSP” on July 1, 2026. The offering is expected to close on July 2, 2026, subject to customary closing conditions. In addition, Bending Spoons and the Selling Shareholders granted the underwriters an option to purchase up to an additional 5,244,026 ordinary shares from Bending Spoons and up to an additional 3,451,626 ordinary shares from the Selling Shareholders at the initial public offering price, less underwriting

FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 19:19:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease and lung cancer,” she added. “More broadly, it reinforces the agency’s science-based approach to evaluating products across the co

Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 18:00:00 EEST | Press release

Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye